Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021835 | 0.90 | KMT2A (0.42) | MAPTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL3130519 | 0.84 | RAB9A (0.39) | MAPTHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3011433 | 0.84 | CYP1A2 (0.44) | MAPTMEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL3018879 | 0.83 | MEN1 (0.48) | MAPTMEN1KMT2ASMN1; SMN2MAOB | |
| SCHEMBL3010875 | 0.74 | KMT2A (0.54) | MAPTTRPV1HTTMEN1KMT2A | |
| SCHEMBL3010871 | 0.74 | KMT2A (0.54) | MAPTTRPV1HTTMEN1KMT2A | |
| SCHEMBL1284480 | 0.72 | TRPV1 (0.62) | MAPTTRPV1MEN1KMT2AMAOB | |
| SCHEMBL1284478 | 0.72 | TRPV1 (0.62) | MAPTTRPV1MEN1KMT2AMAOB | |
| SCHEMBL30913843 | 0.72 | TRPV1 (0.62) | MAPTTRPV1MEN1KMT2AMAOB | |
| SCHEMBL10891855 | 0.70 | MAPT (0.59) | MAPTHTTMAOBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9162991-B2 | Cinnamoyl inhibitors of transglutaminase | UNIVERSITY OF OTTAWA (CA) | 2015-10-20 | — | — | US | disclosed |
| US-20140024837-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | UNIVERSITE DE MONTREAL (CA) | 2014-01-23 | — | — | US | disclosed |
| US-8614233-B2 | Cinnamoyl inhibitors of transglutaminase | UNIVERSITE DE MONTREAL (CA) | 2013-12-24 | — | — | US | disclosed |
| US-20100204280-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | UNIVERSITE DE MONTREAL (CA) | 2010-08-12 | — | — | US | disclosed |
| WO-2008144933-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | Université de Montréal (CA) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204280-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | TGM2, TGM3, TGM1 | MAPT 1920/4885TRPV1 4435/4885HTT 2889/4885 |
| US-20140024837-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | TGM2, TGM3, TFPI | MAPT 2474/4885TRPV1 4488/4885HTT 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.